FIG. 3.
Anti-HIV activity of combinations of ITI-367 and approved anti-HIV drugs. Cultures of tonsil-derived T lymphocytes were infected with a primary R5 HIV-1 isolate M1 and cultured in the presence of the indicated concentrations of ITI-367 in combination with various concentrations of the nonnucleoside reverse transcriptase inhibitor (NNRTI) Efavirenz (panel a), the nucleoside reverse transcriptase inhibitors (NRTIs) AZT (panel b) or d4T (panel c), or the protease inhibitors (PIs) Saquinavir (panel d) or Nelfinavir (panel e). Virus replication was analyzed by measuring p24 in the culture supernatant on day 7 after infection. The data are presented as means of the results for three independent wells.